drugset / Trial / NCT04425564
Study of Metronomic Capecitabine and Oxaliplatin Versus XELOX in Egyptian Metastatic Colorectal Cancer Patients
RandomizedParallel-groupOpen-labelOther
Summary
Colorectal cancer (CRC) in Egypt is advanced tumors at diagnosis. Although, the dramatic increase in efficacy, reduction of mortality, and improvements in survival by the use of standard doses of chemotherapy, some CRC patients suffer from severe toxicities besides disease progression. Use of chemotherapy less than the maximum tolerated dose, with no prolonged drug free breaks incapacitates the cells to engage in progression mechanisms, suggesting that it could be a better alternative to standard dose therapy with better toxicity profile
Timeline
- Start
- 2016-01-01
- Primary completion
- 2017-06-30
- Completion
- 2019-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Capecitabine | Small molecule | 1000 mg/m2 | — |
| Subject | Capecitabine | Small molecule | 2000 mg | — |
| Subject | Oxaliplatin | Small molecule | 30 mg/m2 | — |
| Subject | Oxaliplatin | Small molecule | 130 mg/m2 | — |